Abstract

BackgroundNailfold videocapillaroscopy (NVC) safely allows the detection of microvascular damage which can vary in terms of extent and severity (validated NVC patterns) in patients with Raynaud’s phenomenon (RP) secondary to...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Microvascular damage in autoimmune connective tissue diseases: a capillaroscopic analysis from 20 years of experience in a EULAR training and research referral centre for imaging
Alberto Sulli ... Maurizio Cutolo
RMD Open | VOL. 9
Alberto Sulli, et. al.Alberto Sulli ... Maurizio Cutolo
01 Jul 2023
POS0862 NAILFOLD CAPILLAROSCOPY IN UNDIFFERENTIATED AND MIXED CONNECTIVE TISSUE DISEASES
G Ferrari ... S Paolino
-
G Ferrari, et. al.G Ferrari ... S Paolino
19 May 2021
Capillaroscopic analysis of the microvascular status in mixed versus undifferentiated connective tissue disease.
Maurizio Cutolo ... Vanessa Smith
Microvascular research | VOL. 142
Maurizio Cutolo, et. al.Maurizio Cutolo ... Vanessa Smith
01 Jul 2022
AB0758 Evaluation of nailfold video capillaroscopy in 296 patients with connective tissue diseases
L Czirják ... G Kumánovics
Annals of the Rheumatic Diseases | VOL. 77
L Czirják, et. al.L Czirják ... G Kumánovics
01 Jun 2018
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers